Conolidine’s analgesic outcomes stem from its conversation with non-opioid pain pathways. Contrary to opioids, which bind to µ-opioid receptors from the central anxious method, conolidine modulates alternate molecular targets. A Science Innovations review located that conolidine interacts While using the atypical chemokine receptor ACKR3/CXCR7, which regulates opioid peptide availabil... https://altone307fwj2.howeweb.com/profile